NASDAQ · DMRA
Damora Therapeutics, Inc.
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
Loading market information…
NASDAQ · BGLC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BioNexus Gene Lab Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioNexus Gene Lab Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$22.01+$0.40 (+1.85%)
Damora Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.58% below the high.
$6.63-$0.17 (-2.5%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
$0.29+$0.03 (+11.36%)
AEON Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.72% below the high.
$1.86+$0.03 (+1.64%)
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
$5.91+$0.16 (+2.78%)
Lifeward Ltd.’s quoted price sits in the lower half of its reported 52-week range, 38.5% below the high.
$8.26-$1.44 (-14.84%)
Aptorum Group Limited’s quoted price sits in the lower half of its reported 52-week range, 81.52% below the high.
$2.64-$0.34 (-11.41%)
Advanced Biomed Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 89.1% below the high.
$0.39+$0.03 (+9.0%)
Mustang Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.66% below the high.
